InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.
| Revenue (Most Recent Fiscal Year) | $0.03M |
| Net Income (Most Recent Fiscal Year) | $-51.63M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.99 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -149706.05% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -53.56% |
| Return on Assets (Trailing 12 Months) | -43.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.22 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 3.70 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.15 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.11 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.77 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.58 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 147.37M |
| Free Float | 123.35M |
| Market Capitalization | $337.47M |
| Average Volume (Last 20 Days) | 1.03M |
| Beta (Past 60 Months) | 2.52 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 42.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |